We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
HQY benefits from solid Q3 results and expanding HSAs, including rising HSA assets and investment accounts.
HQY advances AI tools like claims adjudication and Agentic AI to speed service and boost satisfaction.
HQY faces ongoing data security risks, including $0.3M in fraud reimbursements in the quarter.
HealthEquity, Inc. (HQY - Free Report) has been gaining from its business model and strategy. The optimism, led by a solid fourth-quarter fiscal 2026 performance and strength in Health Savings Accounts (HSAs), is expected to contribute further. However, data security threats are major concerns.
In the past six months, the Zacks Rank #3 (Hold) company’s shares have lost 9% compared with 10.6% decline of the industry. The S&P 500 has lost 4.9% during the said time frame.
The renowned provider of technology-enabled services platforms for healthcare savings and spending decisions has a market capitalization of $7.06 billion. The company projects 21% growth over the next five years and expects to witness continued improvements in its business. HealthEquity’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 14.03%.
Image Source: Zacks Investment Research
Reasons Favoring HQY’s Growth
AI & Digital Innovation Drive Scalable Efficiency: In fourth-quarter fiscal 2026, HealthEquity further advanced its AI and digital innovation strategy, with management now framing AI as an active driver of operating leverage rather than a forward-looking initiative. The company highlighted that AI-enabled tools, including expedited claims processing, intelligent self-service solutions and evolving agentic support capabilities, are already reducing reliance on phone-based interactions, lowering service costs and improving resolution speed. These efficiencies contributed to a $17 million year-over-year decline in service costs and supported more than 700 basis points of gross margin expansion, demonstrating that automation and digital workflows are translating into tangible financial benefits.
Expansion of Health Savings Accounts: HealthEquity has experienced significant growth in its HSA offerings. As of Jan. 31, 2026, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10.6 million, up 7% year over year.
HealthEquity reported 832,000 HSAs with investments as of Jan. 31, 2026, up 10% year over year. Total accounts, as of Jan. 31, 2026, were 17.8 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs).
Total HSA assets were $36.5 billion at the end of Jan. 31, 2026, up 14% year over year. This included $18 billion of HSA cash and $18.5 billion of HSA investments.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $1.1 billion as of Jan. 31, 2026.
Strong Q4 Results: HealthEquity exited fourth-quarter fiscal 2026 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Significant improvements in operating and gross margins also bode well.
HealthEquity reported strong account growth momentum exiting fiscal 2026, adding a record 550,000 HSAs in the fiscal fourth quarter and more than 1 million new HSAs for the full year, bringing total accounts to 17.8 million. Management emphasized that this growth reflects robust execution across new sales, high retention levels (above 98%) and continued adoption of HSA-qualified plans.
A Factor That May Offset HQY’s Gains
Data Security Threats: HealthEquity manages highly sensitive personal data and more than $34 billion of client HSA assets, making platform security a persistent operational risk. While fraud reimbursements declined to approximately $0.3 million in the fiscal third quarter of 2026, management continues to invest heavily in fraud prevention and security controls, underscoring that the threat remains structural rather than eliminated. Any material security breach could result in the loss of funds or sensitive data, litigation, regulatory scrutiny and reputational damage, potentially disrupting operations, pressuring margins and eroding client and member confidence.
Estimate Trend
HealthEquity has been witnessing a positive estimate revision trend for fiscal 2027. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved upward by 2 cents to $4.60.
The Zacks Consensus Estimate for first-quarter fiscal 2027 revenues is pegged at $354.4 million, implying a 7.1% rise from the year-ago reported number. The consensus mark for fiscal first-quarter EPS is pinned at $1.11, implying a 14.4% improvement year over year.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
Key Takeaways
HealthEquity, Inc. (HQY - Free Report) has been gaining from its business model and strategy. The optimism, led by a solid fourth-quarter fiscal 2026 performance and strength in Health Savings Accounts (HSAs), is expected to contribute further. However, data security threats are major concerns.
In the past six months, the Zacks Rank #3 (Hold) company’s shares have lost 9% compared with 10.6% decline of the industry. The S&P 500 has lost 4.9% during the said time frame.
The renowned provider of technology-enabled services platforms for healthcare savings and spending decisions has a market capitalization of $7.06 billion. The company projects 21% growth over the next five years and expects to witness continued improvements in its business. HealthEquity’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 14.03%.
Image Source: Zacks Investment Research
Reasons Favoring HQY’s Growth
AI & Digital Innovation Drive Scalable Efficiency: In fourth-quarter fiscal 2026, HealthEquity further advanced its AI and digital innovation strategy, with management now framing AI as an active driver of operating leverage rather than a forward-looking initiative. The company highlighted that AI-enabled tools, including expedited claims processing, intelligent self-service solutions and evolving agentic support capabilities, are already reducing reliance on phone-based interactions, lowering service costs and improving resolution speed. These efficiencies contributed to a $17 million year-over-year decline in service costs and supported more than 700 basis points of gross margin expansion, demonstrating that automation and digital workflows are translating into tangible financial benefits.
Expansion of Health Savings Accounts: HealthEquity has experienced significant growth in its HSA offerings. As of Jan. 31, 2026, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10.6 million, up 7% year over year.
HealthEquity reported 832,000 HSAs with investments as of Jan. 31, 2026, up 10% year over year. Total accounts, as of Jan. 31, 2026, were 17.8 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs).
Total HSA assets were $36.5 billion at the end of Jan. 31, 2026, up 14% year over year. This included $18 billion of HSA cash and $18.5 billion of HSA investments.
Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $1.1 billion as of Jan. 31, 2026.
Strong Q4 Results: HealthEquity exited fourth-quarter fiscal 2026 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Significant improvements in operating and gross margins also bode well.
HealthEquity reported strong account growth momentum exiting fiscal 2026, adding a record 550,000 HSAs in the fiscal fourth quarter and more than 1 million new HSAs for the full year, bringing total accounts to 17.8 million. Management emphasized that this growth reflects robust execution across new sales, high retention levels (above 98%) and continued adoption of HSA-qualified plans.
A Factor That May Offset HQY’s Gains
Data Security Threats: HealthEquity manages highly sensitive personal data and more than $34 billion of client HSA assets, making platform security a persistent operational risk. While fraud reimbursements declined to approximately $0.3 million in the fiscal third quarter of 2026, management continues to invest heavily in fraud prevention and security controls, underscoring that the threat remains structural rather than eliminated. Any material security breach could result in the loss of funds or sensitive data, litigation, regulatory scrutiny and reputational damage, potentially disrupting operations, pressuring margins and eroding client and member confidence.
Estimate Trend
HealthEquity has been witnessing a positive estimate revision trend for fiscal 2027. Over the past 30 days, the Zacks Consensus Estimate for earnings per share (EPS) has moved upward by 2 cents to $4.60.
The Zacks Consensus Estimate for first-quarter fiscal 2027 revenues is pegged at $354.4 million, implying a 7.1% rise from the year-ago reported number. The consensus mark for fiscal first-quarter EPS is pinned at $1.11, implying a 14.4% improvement year over year.
Key Picks
Some better-ranked stocks in the broader medical space are Envista (NVST - Free Report) , Globus Medical (GMED - Free Report) and BrightSpring Health Services (BTSG - Free Report) . Each stock presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.